Compare MakeMyTrip Ltd (MMYT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MakeMyTrip Ltd vs Recursion Pharmaceuticals Inc — how do they compare? MakeMyTrip Ltd trades at $60.56 (market cap $5.78B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: MakeMyTrip Ltd is far larger — about 3.2× Recursion Pharmaceuticals Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| MMYT | RXRX | |
|---|---|---|
Market Cap | $5.78B | $1.81B |
Sector | Technology | Health |
52-Week High | $103.21 | $6.79 |
52-Week Low | $36.30 | $2.84 |
Enterprise Value | $6.44B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MakeMyTrip (MMYT) trades at $60.30, down 1.0% today, with strong technical momentum indicated by bullish moving averages. The company reported Q1 2027 earnings that beat expectations despite revenue headwinds, maintaining robust gross margins of 73.45%. Recent news highlights growth in hotels and packages segments offsetting air travel softness, with analyst consensus strongly bullish at 73% buy ratings.
The outlook remains positive with earnings momentum and diversified travel services driving growth, though elevated P/E ratio of 267 and geopolitical travel disruptions present risks. Institutional sentiment supports upside potential with 34% average price target, while balance sheet strength provides stability amid market volatility.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
